The government is consulting on proposed changes to legislation to ensure that the overall growth of branded medicines sales made to the NHS by pharmaceutical manufacturers in the statutory medicines pricing scheme remains at a sustainable level.
The consultation seeks views on:
- the methodology for forecasting expected future branded medicines growth
- proposed changes to the method of calculating a payment percentage, based on allowed growth rates
- minor technical changes to the products in scope of payment